Punita's expertise lies predominantly in the area of biotechnology, with a specific focus on the technical fields of Agbio, diagnostics including point of care lateral flow tests, personalized medicine, biologics and gene therapy. Her experience also includes leading multi-disciplinary teams handling innovations which span the life sciences and electronics sectors. At both a personal and professional level, Punita is keenly interested in sustainable technology, in particular the ways in which the life sciences sector can improve sustainability to address key problems such as plastic pollution, packaging and the food industry.
Punita has worked extensively with multinational corporations, universities, and small to medium sized enterprises. She has a practical and commercially focused approach, and over the course of her career has assisted numerous small companies with IP portfolio management, with a focus toward building a robust patent strategy.
Punita is highly experienced in obtaining commercially valuable patent protection for her clients. Her practice includes routinely managing large global patent portfolios, as well as conducting due diligence to support corporate acquisition and investment, conducting freedom to operate analysis, and advising her clients on third party rights and infringement. Punita has defended her clients patent rights and commercial position in leading opposition and appeal proceedings before the EPO.
MA (Cantab) Natural Sciences
November 16th 2020
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.